The Estée Lauder Companies Announces New Equity and Engagement Center of Excellence
4.3.2021 15:00:00 EET | Business Wire | Press release
The Estée Lauder Companies (NYSE:EL) announced today that it has established a new Equity and Engagement Center of Excellence (COE). The creation of this new capability underscores The Estée Lauder Companies’ (ELC) core values and commitments to build greater equity and representation within every aspect of its business, from its employees to its consumers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005218/en/
Nicole Monson Appointed to Lead COE as Senior Vice President, Equity and Engagement (Photo: Business Wire)
The Equity and Engagement COE will be led by Nicole Monson, who has been appointed Senior Vice President, Equity and Engagement. Nicole will report directly to Michael O’Hare, Executive Vice President, Global Human Resources.
The events of 2020 and the movement around racial equality have placed a necessary spotlight on every company’s responsibility to take action to advance equal representation, advocacy and inclusion across their organizations. From examining and evolving how the company engages with employees around the world, to enabling greater collaboration across its brands, regions and functions, ELC remains dedicated to purposeful, strategic and accelerated action to drive lasting change.
Building upon ELC’s existing Commitment to Act on Racial Equity, actions on pay equity and other activities to date, the creation of the Equity and Engagement COE signals ELC’s investment in a focused and holistic approach to drive sustainable progress and advance the company’s diverse talent through deep engagement, career advancement, development programs, hiring practices and beyond.
“Our collective vision is to be the most inclusive, equitable and diverse global prestige beauty company for our employees and consumers alike. This important new capability will enhance employee engagement and build greater equity across the business today, while also providing a strategic platform to expand and scale this work into the future,” said Fabrizio Freda, President and Chief Executive Officer. “We know that authentic change takes time, dedication and a clear strategy, and we will continue to devote focused and meaningful resources toward accelerating this goal.”
“Since our company’s founding, our talented employees have been at the center of our business and the most important driver of our success. While we are proud of the progress we have made as a company thus far, we are committed to driving equity and engagement for the long-term,” said William P. Lauder, Executive Chairman. “Nicole’s deep experience and extensive knowledge of Human Resources and the global legal environment, combined with her demonstrated ability to positively influence ELC’s culture, have been invaluable to the company. I look forward to her continued leadership at the helm of this new Center of Excellence.”
As Senior Vice President, Equity and Engagement, Nicole will be an important member of ELC’s Senior Leadership Team and she will work across all areas of the business to develop the company’s long-term Equity and employee Engagement strategy and enterprise-wide capabilities. She will lead the development and implementation of proactive Equity and Engagement initiatives to create a workforce that is more representative and responsive to people of all backgrounds, where all have an opportunity to succeed.
The Equity and Engagement COE was designed to be a strategic and complementary enterprise-wide partner to ELC’s other leaders and business units focused on ESG-related matters, including Human Resources, the Inclusion, Diversity & Equity (IDE) COE, Global Communications, Global Citizenship and Sustainability (GCCS), Global Public Affairs, and beyond. In this spirit, Nicole will collaborate closely with Human Resources leaders and the IDE COE to develop programs designed to ensure fair, inclusive, and equitable treatment of employees around the world with emphasis on addressing conflict and implementing support systems for employees of color, ensuring equitable compensation, application of policies and access to career paths and ensuring the execution of ELC’s equity and engagement vision and strategy. Additionally, Nicole will lead the company’s Racial Equity Initiative, which includes finalizing and implementing a strategy to ensure ELC achieves its Racial Equity Commitments.
Nicole has an extensive proven track record of providing business partners with strategic legal counsel on a wide range of employment and compliance topics, a background that will serve her well in her new role. In her most recent position as Senior Vice President, Deputy General Counsel, Global Employment, Ethics and Legal Privacy, Nicole oversaw the Employment Law, Ethics and Legal Privacy teams and worked to advance the Legal strategy for employment, ethics and privacy globally to protect the company’s interests and mitigate risks associated with new laws and regulations, growth of digital platforms, new global acquisitions and an increased regulatory environment. Since joining the company in 2014 as Vice President, Employment Counsel, her role has continuously expanded and evolved with new responsibilities.
Nicole’s influence on ELC’s organizational culture has extended far beyond her official role and responsibilities. As a member of ELC’s Diversity Council, as well as ELC’s ‘Network of Black Leaders & Executives’ and ‘Women’s Leadership Network’ Employee Resource Groups, Nicole has long been passionate about promoting a culture of respect, inclusivity and belonging. Recently, she became Executive Sponsor of She’s Howard: Own Your Power, ELC’s partnership with Howard University to support the success of the University’s alumnae through experiential learning, career coaching, professional training and self-empowering mentorship opportunities.
In addition to her many contributions to ELC, Nicole is a highly regarded expert and thought leader. She has been a guest speaker for numerous local and national organizations. Notably, Nicole was also selected for inclusion into the National Black Lawyers Top 100, an elite network of successful and influential lawyers with reputations for providing excellent legal representation in their respective practice areas.
Nicole has more than 20 years of relevant experience across labor and employment law and compliance. She earned her J.D. from Howard University School of Law and her B.A. from Spelman College.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005218/en/
Contact information
Investor Relations:
Rainey Mancini
rmancini@estee.com
Media Relations:
Jill Marvin
jmarvin@estee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
